CDNA CareDx, Inc.

CIK 0001217234 50 ready 8-Ks latest July 30, 2026, 4:03 PM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing July 30, 2026, 4:03 PM ET

Top materiality 0.90

Event mix earnings ×21 · leadership ×11 · other_material ×10

Sentiment 21 pos · 6 neg · 23 neu

Latest earnings reported 2025-FY

Executive change recent →

Recent 8-K filings for CDNA

Highest-materiality recent filing

CareDx acquires Naveris for $160M; Q1 revenue $118M (+39% YoY), raises 2026 guidance

April 28, 2026, 7:59 PM ET M&A materiality 0.90 positive item 1.01 item 2.02 item 9.01 item 7.01 item 8.01 ◈ Earnings Releases◈ Material Agreements

Upfront cash $160M for Naveris, plus up to $100M in revenue milestones; expands into viral-mediated cancer MRD surveillance.
Q1 revenue $118M (+39% YoY); Testing Services revenue $91M (+48% YoY); GAAP net income $3M vs loss $10M prior year.

Read filing →

July 30, 2026, 4:03 PM ET earnings materiality 0.85 positive item 2.02 item 9.01 item 7.01

CareDx Q2 revenue $132M (+52% YoY); raises FY2026 revenue guidance to $490M-$500M

Q2 revenue $132M (+52% YoY); Testing Services revenue $100M (+61% YoY) on ~58,000 tests.
July 7, 2026, 5:12 PM ET M&A materiality 0.85 positive item 2.01 item 7.01 item 9.01

CareDx closes $171M sale of Lab Products to Eurobio, acquires Naveris for $162M+

Sale of Lab Products business to Eurobio closed June 30 for $171.2M cash, sharpening focus on U.S. testing services.
April 28, 2026, 7:59 PM ET M&A materiality 0.90 positive item 1.01 item 2.02 item 9.01 item 7.01 item 8.01 ◈ Earnings Releases◈ Material Agreements

CareDx acquires Naveris for $160M; Q1 revenue $118M (+39% YoY), raises 2026 guidance

Upfront cash $160M for Naveris, plus up to $100M in revenue milestones; expands into viral-mediated cancer MRD surveillance.
April 16, 2026, 7:59 PM ET M&A materiality 0.85 positive item 1.01 item 2.02 item 7.01 item 9.01 ◈ Earnings Releases◈ Material Agreements

CareDx sells Lab Products to Eurobio for $170M; Q1 rev up 39% to $118M

Divests Lab Products (IVD kits) to Eurobio Scientific for $170M cash; expected close by end of Q3 2026.
February 25, 2026, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01 item 5.02 item 7.01

CareDx Q4 rev $108M +25% YoY, FY25 rev $380M; FY26 guide $420-444M; CFO resigns, Kennedy appointed

Q4 revenue $108M (+25% YoY); full-year revenue $380M (+14%). FY2026 guidance $420-444M.
February 24, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 item 5.02 item 7.01

CareDx Q4 revenue up 25% to $108M, guides FY2026 revenue $420M-$444M; CFO resigns, Kennedy appointed

Full year 2025 revenue $380M (+14% YoY); Q4 revenue $108M (+25% YoY).
January 12, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

CareDx prelim Q4 revenue ~$108M (+25% YoY); FY25 rev ~$380M (+14%)

Q4 testing services volume ~53,000 (+17% YoY); testing revenue ~$78M (+23%).
November 4, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 item 7.01

CareDx Q3 revenue $100.1M (+21% YoY), turns to GAAP net income $1.7M; raises FY guidance

Revenue $100.1M, up 21% YoY; testing services volume ~50,300 (+13% YoY).
August 6, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 item 5.02 item 7.01

CareDx Q2 adjusted revenue up 14% YoY to $90.5M; narrows FY guidance; appoints new CFO

Q2 adjusted revenue $90.5M (+14% YoY); GAAP revenue $86.7M (-6% YoY) due to $3.8M aged receivable write-off.
June 3, 2025, 7:59 PM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

CareDx completes $50M buyback (5% shares), authorizes new $50M program

Completed $50M repurchase of ~3.03M shares, representing 5% of outstanding common stock.
April 30, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

CareDx Q1 revenue $84.7M (+18% YoY); GAAP net loss narrows to $10.4M; non-GAAP net income $5.4M

Revenue $84.7M (+18% YoY); testing services revenue $61.9M (+15%), volume ~47,100 (+12% YoY).
February 26, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01 item 7.01

CareDx Q4 revenue $86.6M (+32% YoY), FY2025 guidance $365-375M; $50M buyback

Q4 revenue $86.6M (+32% YoY); testing services revenue $63.8M (+37%); volume ~45,500 tests (+14%).
January 13, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 item 7.01

CareDx reports preliminary Q4 revenue up 30% YoY to ~$85.5M; guides 2025 revenue $370M

Q4 revenue expected $85M-$86M, up ~30% YoY; testing services revenue $62.5M-$63.5M, up 35%.
November 4, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

CareDx Q3 revenue $82.9M (+23% YoY), raises FY guidance to $327-331M with positive EBITDA $6.9M

Revenue $82.9M (+23% YoY); testing services rev $60.8M (+27%); volume 44,600 tests (+16%).
October 15, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 item 7.01

CareDx reports preliminary Q3 revenue of $82-83M, up 23% YoY; testing volume rises 16%

Preliminary Q3 2024 revenue $82-83M, up ~23% YoY; testing services $60-61M (+26%).
October 8, 2024, 7:59 PM ET regulatory materiality 0.75 positive item 8.01

CareDx: DOJ declines to intervene in qui tam, closes investigation; SEC closes probe

On Oct 7, 2024, DOJ notified court it declines to intervene in qui tam filed by former employee; investigation closed.
July 31, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

CareDx Q2 revenue $92.3M (+31% YoY); raises FY2024 revenue guidance to $320-$328M

Total revenue $92.3M (+31% YoY); Testing Services revenue $70.9M (+33%); volume 43,700 tests (+17%).
May 9, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases

CareDx Q1 revenue $72M (-7% YoY); raises FY2024 revenue guidance to $274-282M

Revenue $72.0M, down 7% YoY from $77.3M but up 10% sequentially from Q4 2023.
April 16, 2024, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 item 8.01 item 9.01 ◈ executive_change ×2

CareDx appoints John W. Hanna as President and CEO effective April 15, 2024

John Hanna appointed CEO and Class III director, effective April 15, 2024.
February 28, 2024, 6:59 PM ET earnings materiality 0.85 negative item 2.02 item 9.01 item 7.01

CareDx reports FY2023 revenue $280.3M, exceeding guidance; Q4 net loss includes $96.3M patent accrual

Full-year revenue $280.3M, down 13% YoY; Testing Services revenue $209.7M, down 20%.
January 9, 2024, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 item 7.01 ◈ Earnings Releases ×2

CareDx prelim FY2023 revenue $279-280M, above high end of guidance; Q4 patient volumes up 4% QoQ

Full-year revenue expected $279-280M, exceeding $277M high-end guidance; FY2022 was $321.8M.
November 8, 2023, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases

CareDx Q3 revenue $67.2M (-15% YoY); net loss $23.5M; raises FY2023 guidance to $274-278M

Revenue $67.2M (-15% YoY); testing services $47.8M (-26% YoY).
November 1, 2023, 7:59 PM ET leadership materiality 0.80 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×3

CareDx CEO Seeto resigns; Board forms Office of CEO, raises FY2023 revenue guidance to $274-278M

CEO Reginald Seeto resigns effective Nov 1, 2023; transitions to Senior Advisor; receives $51,666/mo for 14 months plus $620K target bonus.
September 25, 2023, 7:59 PM ET regulatory materiality 0.75 positive item 8.01

SEC closes investigation into CareDx without enforcement action

SEC notified CareDx on Sept 19, 2023, that it concluded investigation and will not recommend enforcement action.
August 8, 2023, 7:59 PM ET earnings materiality 0.70 negative item 2.02 item 9.01

CareDx Q2 2023 revenue $70.3M (-13% YoY); net loss $0.46 per share vs $0.41 loss last year

Testing services revenue $53.4M, down 20% YoY due to Medicare Billing Article revisions.
May 10, 2023, 7:59 PM ET earnings materiality 0.70 negative item 2.02 item 9.01 ◈ Earnings Releases

CareDx Q1 revenue $77.3M (-3% YoY); withdraws 2023 guidance on billing article uncertainty

Record test volumes 49,900 (AlloMap/AlloSure), up 17% YoY; testing services revenue $61.8M.
February 27, 2023, 6:59 PM ET earnings materiality 0.65 negative item 2.02 item 9.01 ◈ Earnings Releases ×2

CareDx Q4 revenue $82.4M (+4% YoY); net loss widens to $18.3M; guides for H1 2023 EBITDA profitability

Full year 2022 revenue $321.8M (+9% YoY); testing volumes up 19% to ~182,000 tests.
January 9, 2023, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 item 7.01 ◈ Earnings Releases ×2

CareDx prelim Q4 rev $81.9-82.2M (+4% YoY); FY22 rev ~$321M (+8%); $50M buyback authorized

Preliminary Q4 2022 revenue $81.9-82.2M vs $79.2M in Q4 2021; testing services rev $64.9-65.2M (down from $68.6M).
November 3, 2022, 7:59 PM ET earnings materiality 0.60 negative item 2.02 item 9.01 ◈ Earnings Releases

CareDx Q3: Revenue $79.4M (+5%), net loss widens to $16.9M; adj EBITDA loss $2.5M

Revenue $79.4M (+5% YoY); testing services $64.8M, product $7.2M, patient/digital $7.4M.

Executive changes

Departed

Alexander Johnson

President of Patient and Testing Services

CDNA · CareDx, Inc.

Effective: 2024-09-13
Filed: October 4, 2024, 7:59 PM ET

On September 12, 2024, CareDx, Inc. (the “Company”) announced that the Company reached an agreement with Alexander Johnson, the Company’s President of Patient and Testing Services, pursuant to which Mr. Johnson’s employment would conclude effective as of September 13, 2024 and that such separation would be treated as a termination by the Company without “cause”

Appointed

Keith Kennedy

Chief Operating Officer

CDNA · CareDx, Inc.

Effective: 2024-09-12
Filed: September 12, 2024, 7:59 PM ET

The Board of Directors of CareDx, Inc. (the “Company”) has appointed Keith Kennedy, as the Company’s Chief Operating Officer, effective September 12, 2024 (the “Effective Date”).

Appointed

John W. Hanna

Class III director

CDNA · CareDx, Inc.

Effective: 2024-04-15
Filed: April 16, 2024, 7:59 PM ET

The Board of Directors (the “Board”) of CareDx, Inc. (the “Company”) has appointed John W. Hanna as the Company’s President and Chief Executive Officer and as a Class III director of the Company, in each case effective April 15, 2024 (the “Effective Date”).

Appointed

John W. Hanna

President and Chief Executive Officer

CDNA · CareDx, Inc.

Effective: 2024-04-15
Filed: April 16, 2024, 7:59 PM ET

The Board of Directors (the “Board”) of CareDx, Inc. (the “Company”) has appointed John W. Hanna as the Company’s President and Chief Executive Officer and as a Class III director of the Company, in each case effective April 15, 2024 (the “Effective Date”).

Appointed

R. Bryan Riggsbee

Director

CDNA · CareDx, Inc.

Effective: 2024-03-11
Filed: March 11, 2024, 7:59 PM ET

On March 9, 2024, the board of directors (the “Board”) of CareDx, Inc. (the “Company”) appointed R. Bryan Riggsbee as a Class II director of the Company, effective March 11, 2024.

Departed

Reginald Seeto

President and Chief Executive Officer

CDNA · CareDx, Inc.

Effective: 2023-11-01
Filed: November 1, 2023, 7:59 PM ET

Reginald Seeto, MBBS, the President and Chief Executive Officer of CareDx, Inc. (the “Company”), resigned from the Company.

Departed

Reginald Seeto

Director

CDNA · CareDx, Inc.

Effective: 2023-11-01
Filed: November 1, 2023, 7:59 PM ET

Dr. Seeto also resigned from the Board, effective as of November 1, 2023.

Appointed

Reginald Seeto

Senior Advisor to the Chairperson

CDNA · CareDx, Inc.

Effective: 2023-11-02
Filed: November 1, 2023, 7:59 PM ET

effective November 2, 2023, he will transition to the role of Senior Advisor to the Chairperson

Appointed

Abraham Ronai

Senior Legal Advisor to the Chairperson

CDNA · CareDx, Inc.

Effective: 2023-10-01
Filed: September 26, 2023, 7:59 PM ET

effective October 1, 2023, he will transition to the role of Senior Legal Advisor to the Chairperson of the Board of Directors of the Company

Departed

Abraham Ronai

Chief Administrative & Legal Officer and Secretary

CDNA · CareDx, Inc.

Effective: 2023-09-30
Filed: September 26, 2023, 7:59 PM ET

On September 20, 2023, Abraham Ronai, the Chief Administrative & Legal Officer and Secretary of CareDx, Inc. (the “Company”), resigned from the Company.

Departed

Ralph Snyderman

Director

CDNA · CareDx, Inc.

Effective: 2022-12-31
Filed: November 23, 2022, 6:59 PM ET

On November 21, 2022, Ralph Snyderman, M.D., notified the Board of Directors (the “Board”) of CareDx, Inc. (the “Company”) that he will be resigning from the Board and all committees of the Board, effective as of December 31, 2022.

Appointed

Abhishek Jain

Chief Financial Officer

CDNA · CareDx, Inc.

Effective: 2022-09-07
Filed: September 7, 2022, 7:59 PM ET

Effective September 7, 2022, CareDx, Inc. (the “Company”) appointed Abhishek Jain, age 46, as the Company’s Chief Financial Officer.

Earnings & guidance

2025-FY EPS reported -$0.40 filing →

Materiality & sentiment trend

Max materiality 0.90 · Median 0.70 · Most common event earnings

21 positive 6 negative 23 neutral

source · CDNA on sec.gov